Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors

Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development ofAnti-Claudin-1 (CLDN1) ADCs in solid tumors

Building on its co-lead investments in Alentis Therapeutics' Series B (2021) and Series C (2023) rounds, Jeito's renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones

Financing will advance next-generation targeted therapies for CLDN1 positive tumors

Paris, France, November 12, 2024, Jeito Capital ("Jeito"), a global leading independent Private Equity fund dedicated to biopharma, announced today that it is co-leading a €164.5 million ($181.4 million) oversubscribed Series D financing round in Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for CLDN1 positive (CLDN1+) tumors and organ fibrosis. The financing will support Alentis in advancing its extensive pipeline of CLDN1+ targeted medicines for solid tumors.

The financing was led by new investor, OrbiMed, with existing investors Jeito Capital and Novo Holdings as co-leads. New international investors joining the round include Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital. Existing investors RA Capital Management, Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund and other early institutional investors also participated.

This investment marks Jeito's third round of funding in Alentis, following its co-lead roles in the Series B (June 2021) and Series C (April 2023) financings. Since Jeito's initial investment, Alentis has successfully progressed from early clinical trials to advancing multiple therapeutic programs. These successive investments reflect Jeito's approach of providing both ...